Editorial Comment
Prostate-specific antigen (PSA) screening occurs at an alarming rate among men who will gain no benefit from the diagnosis or treatment of prostate cancer [1]. It has been estimated that 30–50% of men diagnosed with prostate cancer today by PSA testing would otherwise have not known they had cancer during life in the absence of screening (ie, overdiagnosis) [2], [3]. Yet, >90% of